Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Oncopeptides AB | 2,734,591 | net | 17 Mar 2026 | tx 52+2,734,591 |
| SENZIME | 716,344 | net | 23 Sept 2025 | tx 7+716,344 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 17 Mar 2026 | PURCHASE | Oncopeptides AB | 418,876 | 1.55 SEK | |
| 17 Oct 2025 | GRANT_AWARD | Oncopeptides AB | 254,311 | 0.00 SEK | |
| 23 Sept 2025 | PURCHASE | SENZIME | 50,000 | 6.28 SEK | |
| 17 Sept 2025 | PURCHASE | Oncopeptides AB | 146,362 | 3.20 SEK | |
| 16 Sept 2025 | PURCHASE | Oncopeptides AB | 79,590 | 3.20 SEK | |
| 22 Apr 2025 | PURCHASE | SENZIME | 150,000 | 4.07 SEK | |
| 25 Nov 2024 | PURCHASE | SENZIME | 90,000 | 5.71 SEK | |
| 12 Nov 2024 | PURCHASE | SENZIME | 100,000 | 6.14 SEK | |
| 13 Nov 2024 | PURCHASE | SENZIME | 100,000 | 6.10 SEK | |
| 06 Nov 2024 | PURCHASE | SENZIME | 26,344 | 6.20 SEK | |
| 28 Jun 2024 | GRANT_AWARD | Oncopeptides AB | 108,231 | 0.00 SEK | |
| 10 May 2024 | PURCHASE | SENZIME | 200,000 | 0.45 SEK | deriv |
| 03 May 2024 | PURCHASE | Oncopeptides AB | 519,180 | 2.60 SEK | |
| 19 Apr 2024 | PURCHASE | Oncopeptides AB | 204,664 | 2.60 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 1,029 | 26.89 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 176 | 26.95 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 480 | 26.95 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 1,700 | 26.90 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 20 | 26.90 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 1,000 | 26.91 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 2,000 | 26.92 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 1,211 | 26.93 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 1,702 | 26.94 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 2,050 | 27.00 SEK | |
| 30 Aug 2022 | PURCHASE | Oncopeptides AB | 20 | 27.00 SEK |
1 purchase reported after at least 12 months of silence — most recent on 30 Mar 2021.